A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Insulin glargine-aldy identity.
We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.
PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Evidence note
Before
FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.
After
Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.
We added a plain-language reader guide with cited answers, re-checked the Langlara label, and added the Drugs@FDA record and FDA’s April 2026 approval letter.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Langlara
Profile summary
Before
A long-acting insulin analogue. This profile cites a U.S. prescription label.
After
A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes.
Evidence note
Before
The cited DailyMed label identifies Insulin glargine-aldy and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.
U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]
After
U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]; U.S. Food and Drug Administration [sources: fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026]
Showing the latest 6 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 15, 2026.
DailyMed lists Structured Product Labeling version 6 for the reviewed Insulin glargine-aldy label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 7 for the reviewed Insulin glargine-aldy label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 1 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Insulin glargine-aldy label family with a published date of 2026-07-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for BLA 761412 with status AP dated 2026-04-29, and names insulin glargine-aldy among the application record's active ingredients.